Navigation Links
Santarus to Webcast Analyst Day and Investor Briefing Presentation on January 19
Date:1/19/2011

SAN DIEGO, Jan. 19, 2011 /PRNewswire/ -- Santarus, Inc. (Nasdaq: SNTS) announces that a live audio webcast and accompanying slide presentation will be provided for its Analyst Day and Investor Briefing.  

Details of the event are as follows:What:Santarus Analyst Day and Investor BriefingWhen:Today, Wednesday, January 19, 2011 at 4:15 p.m. Eastern timeWhere:www.santarus.com (under the Investor Relations link)AGENDA

  • Strategic Overview and 2011 Financial Outlook


  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

  • CYCLOSET® - Clinical/Medical Background


  • Dr. J. Michael Gaziano, Chief, Division of Aging, Brigham & Women’s Hospital,


    Professor of Medicine, Harvard Medical School

  • ULTESA™ (Budesonide MMX®) – Overview and Top-line Phase III Clinical Study Results


  • Dr. Simon P.L. Travis, Consultant Gastroenterologist,


    Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

  • Ulcerative Colitis – Treatment Perspective


  • Dr. William J. Sandborn, Professor of Clinical Medicine and Chief of the Division of Gastroenterology,


    University of California, San Diego

  • RHUCIN® and Hereditary Angioedema (HAE)


  • Dr. Bruce L. Zuraw, Professor of Medicine and Chief, Allergy and Immunology, University of California, San Diego,


    Research Scientist, San Diego VA Healthcare

  • SAN-300 (anti-VLA-1 antibody)


  • Dr. Mark C. Totoritis, Senior Vice President, Biologics, Santarus, Inc.

  • Wrap-up/Question & Answer Session


  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

    How:Live over the Internet – Simply log on to the Investor Relations section of the company's website at www.santarus.comContact:Lippert/Heilshorn & AssociatesNarine Darbinyan310-691-7100About SantarusSantarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.  The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.  

    Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs:  ULTESA™ (budesonide MMX®) for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers' diarrhea.  In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with SAN-300, its anti-VLA-1 antibody, which the company expects to investigate for the treatment of rheumatoid arthritis.  

    Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation:  difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products; and other risks detailed in Santarus' prior press releases as well as in public periodic filings with the Securities and Exchange Commission.

    You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Santarus® and ULTESA™ are trademarks of Santarus, Inc. GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET® is a trademark of VeroScience LLC. MMX® is a trademark of Cosmo Technologies Limited. RHUCIN® is a trademark of Pharming Group NV.


    '/>"/>

    SOURCE Santarus, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2010 Results
    2. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
    3. Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast
    4. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
    5. BD Announces Webcast of Annual Meeting of Shareholders
    6. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
    7. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
    8. Mettler-Toledo International Inc. Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
    9. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
    10. Cepheid to Webcast Upcoming Financial Presentation
    11. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation ... day delivery service for patients in the Washington ... traditional retail pharmacy by providing delivery of medications through the ... for future delivery or delivered within one hour to any ... are excited to bring this invaluable service to ...
    (Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation ... Surgical System to support its strategic sales plan in ... and Virginia.  7D Surgical has entered into an exclusive sales ... medical facilities within those markets. ... Spartan Medical Purchases ...
    (Date:7/27/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST ) ... and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a ... sales at constant currency (organic) grew by 3.9%. ... to $0.60 in the prior-year quarter. Second-quarter 2017 adjusted ...
    Breaking Medicine Technology:
    (Date:8/21/2017)... ... 2017 , ... PIXACORE , an independent full-service agency with a decade ... of the year by MM&M. , This is the first time PIXACORE has made ... the agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent ...
    (Date:8/21/2017)... ... August 21, 2017 , ... The Industrial Designers Society of America ... Ceremony and Gala on Aug. 19, 2017 in Atlanta, GA—revealing which 25 designs ... prestigious and rigorous design competitions. See all the winners at http://www.idsa.org/awards/idea/gallery . , ...
    (Date:8/20/2017)... ... , ... Are you an adult with gluten intolerance or Celiac disease living ... in participating in a research study that focuses on family interactions when dealing with ... relational aspects of adults who have gluten sensitivities who cohabitate with other adults who ...
    (Date:8/19/2017)... ... 18, 2017 , ... President Donald Trump signed into law ... for greater public access to over-the-counter (OTC) hearing aids. , The measure enables ... without being seen by a certified and licensed audiologist. , “The American ...
    (Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of ... saying there are two sides. There are not two sides to hatred, bigotry, discrimination, ... violence and prejudice, and the NPEIV stands against all forms of such hatred and ...
    Breaking Medicine News(10 mins):